Inspirion Wealth Advisors LLC increased its position in shares of Glaukos Corp (NYSE:GKOS) by 7.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,400 shares of the medical instruments supplier’s stock after buying an additional 650 shares during the period. Inspirion Wealth Advisors LLC’s holdings in Glaukos Corp were worth $482,000 as of its most recent filing with the SEC.
A number of other large investors also recently made changes to their positions in GKOS. Great West Life Assurance Co. Can bought a new stake in shares of Glaukos Corp during the first quarter worth $102,000. State Board of Administration of Florida Retirement System raised its stake in shares of Glaukos Corp by 1.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 7,699 shares of the medical instruments supplier’s stock worth $264,000 after buying an additional 140 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Glaukos Corp during the third quarter worth $313,000. Engineers Gate Manager LP bought a new stake in shares of Glaukos Corp during the first quarter worth $372,000. Finally, Chicago Equity Partners LLC bought a new stake in shares of Glaukos Corp during the third quarter worth $387,000. Institutional investors own 77.95% of the company’s stock.
Shares of Glaukos Corp (NYSE:GKOS) traded down 1.23% during midday trading on Friday, reaching $36.83. 519,656 shares of the company were exchanged. The firm has a market capitalization of $1.26 billion, a P/E ratio of 334.82 and a beta of 1.37. The firm has a 50-day moving average of $45.13 and a 200 day moving average of $40.81. Glaukos Corp has a 52 week low of $23.47 and a 52 week high of $52.49.
Glaukos Corp (NYSE:GKOS) last announced its earnings results on Wednesday, March 1st. The medical instruments supplier reported $0.00 earnings per share for the quarter. The company had revenue of $33.17 million during the quarter, compared to analyst estimates of $29.49 million. Glaukos Corp had a net margin of 2.07% and a return on equity of 2.05%. Glaukos Corp’s revenue was up 63.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.07) earnings per share. On average, equities research analysts expect that Glaukos Corp will post $0.21 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Glaukos Corp (GKOS) Shares Bought by Inspirion Wealth Advisors LLC” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/05/20/glaukos-corp-gkos-shares-bought-by-inspirion-wealth-advisors-llc.html.
GKOS has been the subject of a number of research analyst reports. BMO Capital Markets reiterated a “buy” rating and set a $54.00 price objective on shares of Glaukos Corp in a report on Tuesday, April 11th. TheStreet upgraded shares of Glaukos Corp from a “d+” rating to a “c” rating in a report on Wednesday, March 1st. Stephens upgraded shares of Glaukos Corp from an “equal weight” rating to an “overweight” rating in a report on Monday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $54.00 price objective on shares of Glaukos Corp in a report on Thursday, May 4th. Finally, Stifel Nicolaus lifted their price objective on shares of Glaukos Corp from $45.00 to $55.00 and gave the company a “positive” rating in a report on Tuesday, February 28th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $48.17.
In other news, Director Orbimed Advisors Llc sold 382,538 shares of the firm’s stock in a transaction that occurred on Tuesday, March 14th. The shares were sold at an average price of $45.33, for a total value of $17,340,447.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 36.80% of the company’s stock.
Glaukos Corp Company Profile
Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.
Receive News & Ratings for Glaukos Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corp and related companies with MarketBeat.com's FREE daily email newsletter.